Eppendorf opens new site in Singapore
"Asia, with the market regions China and Asia, Pacific, Africa (APA), is an extremely important market for the Eppendorf Group, already accounting for around one third of our total revenue," says Eva van Pelt, Co-CEO of Eppendorf SE. "Singapore is a center of life sciences with a very large growth potential. We are therefore pleased to now be part of this dynamic life science ecosystem with our new location and to be able to further intensify and expand our existing customer relationships."
Customer centricity through customer proximity
Eppendorf's new site is located within Singapore's Biopolis science center, which focuses on biomedical research projects and enables close cooperation between public and private scientific institutions. In addition to modern office space, there is a service center for all Eppendorf equipment, offering repairs, calibrations and validations, as well as a state-of-the-art calibration laboratory for pipettes. The additional purpose-built Bioprocess Center provides scientific and technical support to customers and partners throughout the Asia-Pacific region.
"From Singapore, we can now even better support our customers in scientific, research, healthcare, pharmaceutical and industrial sectors and offer them the relevant products and services within immediate reach," emphasizes Eva van Pelt. "With this investment, we will be able to participate even better in the growth of the life science industry in Asia and continue our strategic approach for even more customer centricity in Asia."
This increased proximity to customers also includes the establishment of a modern and new central warehouse in Singapore. This will make the city-state the logistics hub for Southeast Asia with immediate effect, offering all customers in the region even faster and more reliable delivery.
Biotech & Pharma
Eppendorf divests micro manipulation product portfolio
Biotech & Pharma, Research, Academia & Universities